Indirubin Derivatives in Cancer Therapeutics

Indirubin, a bisindole alkaloid derived from traditional medicinal sources, has emerged as a versatile scaffold for the design of anticancer agents. Structural modification of the parent molecule has yielded a diverse array of derivatives exhibiting improved solubility, target selectivity and pharmacokinetic profiles. Many of these compounds act as kinase inhibitors, with potent activity against cyclin-dependent kinases (CDKs), glycogen synthase kinase-3β (GSK-3β) and other signalling enzymes central to cell proliferation and survival. Mechanistically, indirubin derivatives can induce cell cycle arrest, trigger caspase-mediated apoptosis and inhibit angiogenesis, often with differential effects on mitochondrial respiration and reactive oxygen species production. This multifaceted mode of action has been explored across a spectrum of malignancies, including leukaemias, solid tumours such as melanoma and squamous cell carcinoma, and lymphoid neoplasms. Recent advances have focused on enhancing tumour targeting through nanoparticle encapsulation and on fine-tuning kinase selectivity to minimise off-target toxicity. Together, these efforts position indirubin derivatives as promising candidates for next-generation cancer therapeutics.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Indirubin Derivatives in Cancer Therapeutics publication trend

The graph below shows the total number of articles in indirubin derivatives in cancer therapeutics across all publications each year (not limited to Nature Index journals).

Technical terms

Cyclin-dependent kinases (CDKs): Enzymes that regulate cell-cycle transitions by phosphorylating key substrates.

Glycogen synthase kinase-3β (GSK-3β): A serine/threonine kinase involved in multiple signalling pathways governing cell survival and metabolism.

FLT3: Fms-like tyrosine kinase 3, a receptor kinase frequently mutated in acute myeloid leukaemia, driving malignant proliferation.

Apoptosis: Programmed cell death mediated by a cascade of proteases (caspases), leading to organised cellular dismantling.

Xenograft: Transplantation of human tumour cells into immunodeficient animals to evaluate in vivo drug efficacy.

References

1. A Thia-Analogous Indirubin N-Glycoside Disrupts Mitochondrial Function and Causes the Death of Human Melanoma and Cutaneous Squamous Cell Carcinoma Cells. Cells (2023).
2. Small Molecules in the Treatment of Squamous Cell Carcinomas: Focus on Indirubins. Cancers (2021).
3. Discovery of a FLT3 inhibitor LDD1937 as an anti-leukemic agent for acute myeloid leukemia. Oncotarget (2017).